J Uzan1, A E Nahum. 1. Physics Department, Clatterbridge Cancer Centre, Bebington, UK. Julien.Uzan@clatterbridgecc.nhs.uk
Abstract
OBJECTIVE: Radiobiological models provide a means of evaluating treatment plans. Keeping in mind their inherent limitations, they can also be used prospectively to design new treatment strategies which maximise therapeutic ratio. We propose here a new method to customise fractionation and prescription dose. METHODS: To illustrate our new approach, two non-small cell lung cancer treatment plans and one prostate plan from our archive are analysed using the in-house software tool BioSuite. BioSuite computes normal tissue complication probability and tumour control probability using various radiobiological models and can suggest radiobiologically optimal prescription doses and fractionation schemes with limited toxicity. RESULTS: Dose-response curves present varied aspects depending on the nature of each case. The optimisation process suggests doses and fractionation schemes differing from the original ones. Patterns of optimisation depend on the degree of conformality, the behaviour of the normal tissue (i.e. "serial" or "parallel"), the volume of the tumour and the parameters of clonogen proliferation. CONCLUSION: Individualising the prescription dose and number of fractions with the help of BioSuite results in improved therapeutic ratios as evaluated by radiobiological models.
OBJECTIVE: Radiobiological models provide a means of evaluating treatment plans. Keeping in mind their inherent limitations, they can also be used prospectively to design new treatment strategies which maximise therapeutic ratio. We propose here a new method to customise fractionation and prescription dose. METHODS: To illustrate our new approach, two non-small cell lung cancer treatment plans and one prostate plan from our archive are analysed using the in-house software tool BioSuite. BioSuite computes normal tissue complication probability and tumour control probability using various radiobiological models and can suggest radiobiologically optimal prescription doses and fractionation schemes with limited toxicity. RESULTS: Dose-response curves present varied aspects depending on the nature of each case. The optimisation process suggests doses and fractionation schemes differing from the original ones. Patterns of optimisation depend on the degree of conformality, the behaviour of the normal tissue (i.e. "serial" or "parallel"), the volume of the tumour and the parameters of clonogen proliferation. CONCLUSION: Individualising the prescription dose and number of fractions with the help of BioSuite results in improved therapeutic ratios as evaluated by radiobiological models.
Authors: Andrew Jackson; Lawrence B Marks; Søren M Bentzen; Avraham Eisbruch; Ellen D Yorke; Randal K Ten Haken; Louis S Constine; Joseph O Deasy Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: M Engelsman; P Remeijer; M van Herk; J V Lebesque; B J Mijnheer; E M Damen Journal: Int J Radiat Oncol Biol Phys Date: 2001-12-01 Impact factor: 7.038
Authors: Yvette Seppenwoolde; Joos V Lebesque; Katrien de Jaeger; José S A Belderbos; Liesbeth J Boersma; Cees Schilstra; George T Henning; James A Hayman; Mary K Martel; Randall K Ten Haken Journal: Int J Radiat Oncol Biol Phys Date: 2003-03-01 Impact factor: 7.038
Authors: Alan E Nahum; Benjamin Movsas; Eric M Horwitz; Corinne C Stobbe; J Donald Chapman Journal: Int J Radiat Oncol Biol Phys Date: 2003-10-01 Impact factor: 7.038
Authors: Yijun Ding; Harrison H Barrett; Matthew A Kupinski; Yevgeniy Vinogradskiy; Moyed Miften; Bernard L Jones Journal: Med Phys Date: 2019-06-07 Impact factor: 4.071
Authors: Tonghe Wang; Robert H Press; Matt Giles; Ashesh B Jani; Peter Rossi; Yang Lei; Walter J Curran; Pretesh Patel; Tian Liu; Xiaofeng Yang Journal: Br J Radiol Date: 2019-04-09 Impact factor: 3.039